Press coverage about Aegerion Pharmaceuticals (NASDAQ:AEGR) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aegerion Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 43.8400465061349 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Aegerion Pharmaceuticals (AEGR) traded up $0.10 during trading on Tuesday, reaching $1.97. The company’s stock had a trading volume of 2,168,900 shares, compared to its average volume of 635,262. The company has a market cap of $56.69, a P/E ratio of -0.33 and a beta of 0.50. The company has a quick ratio of 0.67, a current ratio of 1.02 and a debt-to-equity ratio of -19.22. Aegerion Pharmaceuticals has a 12 month low of $1.23 and a 12 month high of $10.85.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Ratings for Aegerion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.